Vijaya Diagnostic Centre announced the approval of its Unaudited Standalone and Consolidated Financial Results for the third quarter ended December 31, 2025. The Board also approved several key executive changes, including the appointment of Mr. Ankit Shah as CFO, effective February 13, 2026. Additionally, two new Non-Executive Independent Directors were appointed, and the resignation of the former CFO was noted.
Board Meeting Outcome: February 13, 2026
The Board of Directors of Vijaya Diagnostic Centre Limited convened on Friday, February 13, 2026, to approve key operational and governance matters. The meeting commenced at 12:30 P.M. and concluded at 02:30 P.M. (IST).
Financial Results Noted
The Board considered and noted the Unaudited Standalone and Consolidated Financial Results of the Company for the third quarter and the nine months ended December 31, 2025.
Key Executive Appointments Approved
Based on recommendations, the Board approved the following high-level appointments, all effective February 13, 2026:
- Appointment of Mr. Ankit Shah as Chief Financial Officer (CFO) & Key Managerial Personnel. Mr. Shah holds a Bachelor’s degree in Commerce and extensive experience in healthcare finance, strategic planning, and corporate governance.
- Appointment of Mr. Sai Siva Prasad as Chief Technology Officer (CTO). Mr. Prasad is a seasoned technology leader with expertise in driving digital transformation across Healthcare and BFSI sectors.
- Appointment of Mr. Venkata Siva Rama Raju Vegesna as Chief Operating Officer (COO). Mr. Vegesna is a Chartered Financial Analyst (CFA) with a background in operational strategy across healthcare and banking sectors.
Furthermore, Mr. Ankit Shah has been authorized by the Board for determining materiality and making disclosures to the stock exchanges, pursuant to Regulation 30(5).
Director Appointments
The Board also approved the appointment of:
- Mr. Ravi Shankararamiah (DIN: 00180746) as an additional director in the capacity of Non-Executive-Independent Director for a period of five (5) years, subject to shareholder approval. Mr. Shankararamiah is a Senior Advocate with over four decades of experience in tax and corporate law.
- Dr. Sasikala Paruchuri Kola (DIN: 00129614) as an additional director in the capacity of Non-Executive-Independent Director for a period of five (5) years, subject to shareholder approval. Dr. Kola is a highly experienced Consultant Gynaecologist and Obstetrician.
CFO Resignation Noted
The Board formally noted the resignation of Mr. S. Ramachandra Reddy from the position of Chief Financial Officer (CFO), effective February 13, 2026. Mr. Reddy is stepping down due to organizational restructuring but will continue to serve the Company in his existing role as General Manager – Finance & Accounts.
Employee Stock Option Grant (ESOPs)
The Board approved the grant of 1,15,000 Employee Stock Options (ESOPs) under the “VDCL Employee Stock Option Plan 2018”. These options are convertible into 1,15,000 equity shares with a face value of ₹1/- each. The Exercise Price for these ESOPs is set at ₹809/- per option, calculated as the average closing price of the preceding three months minus a 20% discount.
Revision to Related Party Transaction Policy
The Board also approved the revision of the Policy for dealing in Related Party Transactions (RPT Policy) based on the recommendations of the Audit Committee, with the revised policy enclosed as Annexure-E.
Source: BSE
